ImmuCell Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
ImmuCell Corporation (ICCC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $4.36 per share for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2025-11-13
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $3.74.
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2017 was $2.28, a 45.06% decline from fiscal 2016.
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2016 was $4.15.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|
| 2025-09-30 | $4.36 10-Q · filed 2025-11-13 | ||
| 2021-12-31 | $3.74 10-K · filed 2022-03-30 | ||
| 2021-09-30 | $3.74 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $3.68 10-Q · filed 2021-08-12 | ||
| 2017-12-31 | $2.28 10-K · filed 2018-03-29 | ||
| 2016-12-31 | $4.15 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |